16:01 , Apr 18, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A panel of patient-derived organoid models of bladder cancer could be used to screen therapies for the indication. The panel consists of 22 bladder cancer organoids generated from 16 patient-derived transurethral tumor...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggest combining Ridaura auranofin and glutathione synthesis inhibitors with RIPK1 or MLKL inhibitors could help treat tuberous sclerosis complex-associated tumors, which are caused by loss-of-function mutations in the...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1); tuberous sclerosis complex tumor suppressor 1 (TSC1)

Ophthalmic disease INDICATION: Retinitis Mouse studies suggest activating mTORC1 in cones could help prevent blindness in retinitis pigmentosa (RP). In mouse models of both fast-progressing and slow-progressing RP, constitutive activation of mTORC1 by cone-specific knockout...
07:00 , Mar 27, 2014 |  BC Innovations  |  Strategy

Explaining the exceptions

A Boston team has identified activating mutations in mammalian target of rapamycin that explain a surprising 14-month complete response seen in 1 patient with bladder cancer receiving Afinitor and Votrient in a Phase I trial....
08:00 , Dec 13, 2012 |  BC Innovations  |  Cover Story

Translating autism

Researchers at McGill University have mouse data showing a causal link between eIF4E -mediated translational dysregulation and autism-related deficits. The group also corrected the dysregulation-and the associated autistic phenotype-with a small molecule. 1 The McGill...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Tuberous sclerosis complex tumor suppressor 1 (TSC1); TSC2; mammalian target of rapamycin (mTOR; FRAP; RAFT1) Genome sequencing suggests mTOR inhibitors may be most...
07:00 , Mar 24, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse model for tuberous sclerosis complex (TSC) Mice lacking a single copy of tuberous sclerosis complex tumor suppressor 1 (Tsc1) in...
08:00 , Dec 4, 2008 |  BC Innovations  |  Cover Story

New strategies for CNS regeneration

Two separate teams of company and university researchers have identified multiple neuronal proteins that could be targeted alone or in combination to promote axon growth and treat spinal cord injury and other forms of CNS...
08:00 , Nov 20, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Phosphatase and tensin homolog (PTEN; MMAC1; TEP1); tuberous sclerosis 1 (TSC1) Studies in mice suggest that PTEN...
07:00 , Mar 27, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Tuberous sclerosis complex (TSC) Mammalian target of rapamycin complex 1 (mTORC1); tuberous sclerosis complex tumor suppressors 1 and 2 (TSC1 and...